Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0MBSAD)
| ADC Name |
VBC103
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
VBC103; VAC-103; AVZO-103
Click to Show/Hide
|
|||||
| Organization |
VelaVigo (Originator);Avenzo Therapeutics
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Antibody Name |
Anti-Nectin-4/TROP2 bispecific VHH-Fc
|
Antibody Info | ||||
| Antigen Name |
Nectin-4 (NECTIN4); Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
TOP1 inhibitor
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | |||
|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
2 Trials
|
||||||
| Urothelial cancer |
1 Trials
|